3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Phase 1
3
Phase 2
2
Status
Active not recruiting
11
Recruiting
4
Terminated
3
Completed
3
Withdrawn
1
Sponsor Class
INDUSTRY
2
NETWORK
1
Study Type
Interventional
3
Sponsor
Cancer Type
Plasma cell
3
Conditions
Multiple Myeloma
3
Interventions
Cyclophosphamide
142
Gemcitabine
129
Paclitaxel
125
Radiotherapy
119
Carboplatin
112
Cisplatin
111
pembrolizumab
110
Nivolumab
106
Docetaxel
90
Rituximab
86
Lenalidomide
77
Dexamethasone
76
Cytarabine
69
Bevacizumab
64
Fluorouracil
63
Etoposide
63
Oxaliplatin
62
Filgrastim
59
Peripheral Blood Stem Cell Transplantation
58
Everolimus
58
Capecitabine
58
fludarabine phosphate
57
Doxorubicin
56
Temozolomide
55
Prednisone
54
Irinotecan
53
Cetuximab
50
fludarabine
48
Ipilimumab
48
Erlotinib Hydrochloride
48
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 1/2
×
Completed
×
belantamab mafodotin
×
Clear all
NCT03544281
2025-03-18
DREAMM 6
GlaxoSmithKline
Phase 1/2
Completed
153 enrolled
91 charts
NCT03732703
2025-02-14
MyDRUG
Multiple Myeloma Research Consortium
Phase 1/2
Completed
103 enrolled
NCT03848845
2024-04-09
DREAMM 4
GlaxoSmithKline
Phase 1/2
Completed
41 enrolled
57 charts